Pliant Therapeutics Inc Stock
Pliant Therapeutics Inc Stock price
Key metrics
| Market capitalization | $83.89m |
| Enterprise Value | $-211.64m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 1.33 |
| P/B ratio (TTM) P/B ratio | 0.27 |
| Revenue growth (TTM) Revenue growth | -100.00% |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-228.37m |
| Free Cash Flow (TTM) Free Cash Flow | $-159.35m |
Is Pliant Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
Pliant Therapeutics Inc Stock Analysis
Analyst Opinions
13 Analysts have issued a Pliant Therapeutics Inc forecast:
Analyst Opinions
13 Analysts have issued a Pliant Therapeutics Inc forecast:
Financial data from Pliant Therapeutics Inc
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -2.13 -2.13 |
2%
2%
|
|
| EBITDA | -226 -226 |
25%
25%
|
EBIT (Operating Income) EBIT | -228 -228 |
24%
24%
|
| Net Profit | -210 -210 |
30%
30%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Pliant Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pliant Therapeutics Inc Stock News
Company Profile
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.
| Head office | United States |
| CEO | Bernard Coulie |
| Employees | 171 |
| Founded | 2015 |
| Website | www.pliantrx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
